mAbxience Invests in OncoPrecision to Develop and Manufacture ONC001 ADC

COMPANY PROFILE
  • mAbxience has entered an investment, development, and manufacturing agreement with OncoPrecision for ONC001, an investigational antibody-drug conjugate (ADC) targeting CD64.
  • The agreement covers antibody development and GMP manufacturing to support the candidate’s planned Phase I clinical trial.

mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, has partnered with New York-based biotechnology company OncoPrecision to develop and manufacture ONC001, an investigational antibody-drug conjugate (ADC) for hard-to-treat blood cancers. Under the agreement, mAbxience will oversee development of the antibody component and manufacture GMP-grade material to support the candidate’s planned Phase I clinical trial.

The development program will cover activities from cell line development (CLD) through process and analytical development, followed by the manufacture of the first GMP batch for clinical use. mAbxience will contribute its antibody development, process development, technology transfer, and manufacturing capabilities, alongside its Smart CoGs approach. The companies aim to advance ONC001 toward first-in-human studies.

ONC001 is a CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages. Its lead indications are monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The candidate was first publicly disclosed in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting and is advancing toward first-in-human studies.

As part of the agreement, mAbxience has made a strategic investment in OncoPrecision. Jurgen Van Broeck, CEO of mAbxience, will join OncoPrecision’s Board of Directors as an Observer. The financial terms of the investment have not been disclosed.

EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.